{"id":"W4221090420","doi":"10.1158/1538-7445.sabcs21-p5-16-13","title":"Abstract P5-16-13: Safety and efficacy of INT230-6, a potential first-in-class intratumoral therapy, in monotherapy and in combination with pembrolizumab: Results from the IT-01 study [KEYNOTE-A10] in subjects with locally advanced, unresectable and metastatic breast cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Dosing; Breast cancer; Response Evaluation Criteria in Solid Tumors; Internal medicine; Tolerability; Oncology; Cancer; Phases of clinical research; Adverse effect; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009485431,0.0008218333,0.001078905,0.0002584787,0.000334343,0.0007253544,0.000618324,0.0008624718,0.0040278],"category_scores_gemma":[0.0004959475,0.0002952962,0.0007154687,0.0002720617,0.0006226301,0.0006874294,0.0002256333,0.002712203,0.001069338],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006239747,"about_ca_system_score_gemma":0.001016004,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001394707,"about_ca_topic_score_gemma":0.001711719,"domain_scores_codex":[0.999665,0.0001201262,0.00002049301,0.00007007978,0.00005923801,0.00006503913],"domain_scores_gemma":[0.9995189,0.00004547062,0.0001141537,0.00003954728,0.0000471146,0.0002348653],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4873344,0.05679275,0.008511339,0.0008922776,0.00150953,0.0005043398,0.0003094575,0.001785292,0.2617566,0.0001885563,0.006234207,0.1741812],"study_design_scores_gemma":[0.1267315,0.7859421,0.02906599,0.00005611263,0.001041712,0.0009556643,0.00009452302,0.001866329,0.04844166,0.0001597762,0.005591698,0.00005290805],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939324,0.002178766,0.0005331871,0.0001988161,0.00004908417,0.0004889661,0.001085918,0.0001015758,0.001431356],"genre_scores_gemma":[0.9938416,0.0008760309,0.0006061055,0.000266333,0.00006204431,0.0002830554,0.001584884,0.00003649637,0.002443416],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0040278,"threshold_uncertainty_score":0.0134744,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02744714685900418,"score_gpt":0.3303014497808328,"score_spread":0.3028543029218286,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}